组织蛋白酶S药理抑制可抑制小鼠腹主动脉瘤
本研究在小鼠氯化钙诱导和血管紧张素II输注两种腹主动脉瘤模型中,评估α-酮酰胺化合物6r抑制组织蛋白酶S的效果。6r治疗减轻了主动脉扩张,降低了组织蛋白酶S和K水平,保护弹性蛋白完整性,减少中膜凋亡细胞和巨噬细胞浸润;诱导后7天或14天开始治疗也限制动脉瘤进展。
要点
- 6r抑制组织蛋白酶S可减轻两种小鼠腹主动脉瘤模型的主动脉扩张。
- 6r治疗降低组织蛋白酶S和K水平,保护弹性蛋白,减少凋亡和炎症。
- 动脉瘤诱导后7天或14天开始6r治疗仍可延缓进展。
核心结论
- 药理抑制组织蛋白酶S的化合物6r可抑制小鼠腹主动脉瘤形成。
- 诱导后7天或14天开始6r治疗可延缓小鼠腹主动脉瘤进展。
- 研究为组织蛋白酶S作为腹主动脉瘤潜在治疗靶点提供概念验证。
研究设计与样本
- 实验研究,采用B6小鼠氯化钙诱导腹主动脉瘤模型和ApoE-/-小鼠血管紧张素II输注模型。
- 氯化钙模型每组n=12,血管紧张素II模型每组n=8。
- 诱导后1天起每3天腹腔注射6r(25 mg/kg)或溶媒,28天评估。
- 氯化钙模型另设诱导后7天或14天开始治疗组,每组n=6,28天评估。
- 主动脉样本进行组织学和生化分析,包括组织蛋白酶水平、Verhoeff Van Gieson染色、TUNEL assay和巨噬细胞免疫染色。
主要发现
- 氯化钙模型中,6r组主动脉扩张中位数0.58 mm,溶媒组0.92 mm(p < .001)。
- 氯化钙模型中,6r降低组织蛋白酶S和K水平(均p < .001),保护弹性蛋白完整性(p < .001),减少中膜凋亡细胞(p = .012)和巨噬细胞浸润(p = .041)。
- 血管紧张素II模型中,6r组主动脉直径中位数0.95 mm,溶媒组1.84 mm(p = .047)。
- 血管紧张素II模型中,6r降低组织蛋白酶S(p < .001)和K(p = .033)水平,减少弹性蛋白断裂(p < .001)、中膜凋亡细胞(p < .001)和浸润巨噬细胞(p = .030)。
- 氯化钙模型中,诱导后7天(p = .046)或14天(p = .012)开始6r治疗限制动脉瘤进展。
临床怎么用
- 目前仅为小鼠实验证据,尚不能直接外推至临床腹主动脉瘤患者。
- 组织蛋白酶S抑制可能成为限制腹主动脉瘤形成和进展的潜在策略,需进一步转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evidence suggests that cathepsin S (CTSS), a potent mammalian elastase, participates in abdominal aortic aneurysm (AAA) formation. This study examines the hypothesis that pharmacological inhibition of CTSS with an α-ketoamide based compound 6r might suppress AAA in mice. METHODS: Experimental study of the CaCl2 induced AAA model in B6 mice and angiotensin II (AngII) infused AAA model in ApoE-/- mice. The effects of intraperitoneal administration of 6r (25 mg/kg) and vehicle every three days since one day after AAA induction were evaluated at 28 days using CaCl2 induced (n = 12 per group) and AngII infused (n = 8 per group) models. Additionally, the effects of post-treatment with 6r and vehicle from seven days or 14 days after AAA induction were evaluated at 28 days using the CaCl2 induced model (n = 6 per group). Aortic samples were harvested for histological and biochemical analyses, including cathepsin levels, Verhoeff Van Gieson staining, TUNEL assay, and immunostaining for macrophages. RESULTS: In the CaCl2 induced model, treatment with 6r suppressed aortic dilatation observed in vehicle treated controls (median: 0.58 vs. 0.92 mm; p < .001), along with reduced CTSS and cathepsin K (CTSK) levels (both p < .001), preserved elastin integrity (p < .001), fewer medial apoptotic cells (p = .012) and less macrophage infiltration (p = .041). In the AngII infused model, the aortic diameter was smaller in 6r treated mice than in vehicle treated controls (median: 0.95 vs. 1.84 mm; p = .047). The levels of CTSS (p < .001) and CTSK (p = .033) and the numbers of elastin breaks (p < .001), medial apoptotic cells (p < .001) and infiltrating macrophages (p = .030) were attenuated under 6r treatment. Finally, post-treatment with 6r from seven days (p = .046) or 14 days (p = .012) after AAA induction limited CaCl2 induced AAA. CONCLUSION: Pharmacological inhibition of CTSS by 6r suppresses AAA formation in mice. Also, post-treatment with 6r retards mouse AAA progression. These findings provide proof of concept validation for CTSS as a potential therapeutic target in AAA.
引用
- Lai CH, Chang JY, Wang KC, et al. Pharmacological Inhibition of Cathepsin S Suppresses Abdominal Aortic Aneurysm in Mice. Eur J Vasc Endovasc Surg. 2020. PMID: 32033870. doi:10.1016/j.ejvs.2020.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。